JP2023546503A - 抗タウ抗体の安全な投与方法 - Google Patents

抗タウ抗体の安全な投与方法 Download PDF

Info

Publication number
JP2023546503A
JP2023546503A JP2023525041A JP2023525041A JP2023546503A JP 2023546503 A JP2023546503 A JP 2023546503A JP 2023525041 A JP2023525041 A JP 2023525041A JP 2023525041 A JP2023525041 A JP 2023525041A JP 2023546503 A JP2023546503 A JP 2023546503A
Authority
JP
Japan
Prior art keywords
tau
amino acid
seq
acid sequence
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023525041A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546503A5 (https=
Inventor
ヘンリー，デイビッド
ナンディ，パルサ
ペレス ルイソ，カルロス
リ，リンジュエ
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2023546503A publication Critical patent/JP2023546503A/ja
Publication of JP2023546503A5 publication Critical patent/JP2023546503A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2023525041A 2020-10-26 2021-10-25 抗タウ抗体の安全な投与方法 Withdrawn JP2023546503A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063105810P 2020-10-26 2020-10-26
US63/105,810 2020-10-26
US202163250114P 2021-09-29 2021-09-29
US63/250,114 2021-09-29
PCT/EP2021/079566 WO2022090169A1 (en) 2020-10-26 2021-10-25 Method of safe administration of anti-tau antibody

Publications (2)

Publication Number Publication Date
JP2023546503A true JP2023546503A (ja) 2023-11-02
JP2023546503A5 JP2023546503A5 (https=) 2024-09-20

Family

ID=78483271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525041A Withdrawn JP2023546503A (ja) 2020-10-26 2021-10-25 抗タウ抗体の安全な投与方法

Country Status (10)

Country Link
US (1) US20220127346A1 (https=)
EP (1) EP4232472A1 (https=)
JP (1) JP2023546503A (https=)
KR (1) KR20230097110A (https=)
AU (1) AU2021370222A1 (https=)
CA (1) CA3199808A1 (https=)
IL (1) IL302383A (https=)
MX (1) MX2023004832A (https=)
TW (1) TW202231661A (https=)
WO (1) WO2022090169A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
US20230235034A1 (en) * 2020-05-26 2023-07-27 The Trustees Of The University Of Pennsylvania Monoclonal antibodies against pathological tau, and methods using same
CA3199806A1 (en) * 2020-10-26 2022-05-05 Janssen Pharmaceutica Nv Methods of reducing tau in human subjects

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170351A1 (en) * 2017-03-16 2018-09-20 Janssen Biotech, Inc. Anti-phf-tau antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US10646569B2 (en) * 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170351A1 (en) * 2017-03-16 2018-09-20 Janssen Biotech, Inc. Anti-phf-tau antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WENDY R. GALPERN; ET AL: "P1-052 A SINGLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY PHARMACOKINETICS, AND PHAR", ALZHEIMER'S & DEMENTIA, vol. VOL.15, NR.7, JPN5024004790, July 2019 (2019-07-01), US, pages 252 - 253, ISSN: 0005683419 *

Also Published As

Publication number Publication date
CA3199808A1 (en) 2022-05-05
AU2021370222A1 (en) 2023-06-22
KR20230097110A (ko) 2023-06-30
IL302383A (en) 2023-06-01
WO2022090169A1 (en) 2022-05-05
TW202231661A (zh) 2022-08-16
US20220127346A1 (en) 2022-04-28
EP4232472A1 (en) 2023-08-30
MX2023004832A (es) 2023-07-18

Similar Documents

Publication Publication Date Title
JP2023546503A (ja) 抗タウ抗体の安全な投与方法
US20240148782A1 (en) Treatment and prevention of alzheimer's disease (ad)
US20220062412A1 (en) Treatment of alzheimer's disease (ad) with an aluminum salt
TW202543674A (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
JP2024547001A (ja) 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法
JP2023546504A (ja) ヒト対象におけるタウを減少させる方法
TW202434633A (zh) 治療甲狀腺眼疾之方法
AU2015254663B2 (en) Treatment and prevention of Alzheimer's Disease (AD)
HK40100358A (zh) 安全施用抗tau抗体的方法
CN116829582A (zh) 安全施用抗Tau抗体的方法
EA051320B1 (ru) Способ безопасного введения антитела к тау-белку
HK40100364A (zh) 减少人类受试者中的tau的方法
Class et al. Patent application title: Methods of Reducing Tau in Human Subjects
WO2025170969A1 (en) Methods of treating al amyloidosis
TW202513583A (zh) 使用抗Ａβ初原纖維抗體之治療方法
WO2026085535A2 (en) Treatment of pathologies associated with down syndrome with anti-fsh antibodies
EA052839B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240911

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260109

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20260126